There are differential patterns of grey matter (GM) atrophy across disease stages of multiple sclerosis (MS), which typically progressed at 1-year of follow-up. In particular, cerebellar GM atrophy predicted clinical progression.
Why this matters
GM is increasingly recognized as a key component in the pathophysiology of MS, and its atrophy has been associated with clinical disability.
Voxel-based morphometry is a conventional approach used to investigate GM atrophy, but is limited in its ability to analyze distinct patterns (or networks) of GM density that usually co-vary between different people.